Page last updated: 2024-08-21

alpha-aminopyridine and Vascular Malformations

alpha-aminopyridine has been researched along with Vascular Malformations in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Angulo-Urarte, A; Baselga, E; Castillo, SD; Celis, V; Esteve-Codina, A; Fanlo, L; Gouveia, L; Graupera, M; Javierre, BM; Kobialka, P; Lavarino, C; López-Fernández, S; Mora, J; Muixí, L; Muñoz-Aznar, O; Olaciregui, NG; Rovira, C; Sabata, H; Vilalta, O; Zanoncello, J	1

Other Studies

1 other study(ies) available for alpha-aminopyridine and Vascular Malformations

Article	Year
The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib. EMBO molecular medicine, 2022, 07-07, Volume: 14, Issue:7 Topics: Aminopyridines; Animals; Class I Phosphatidylinositol 3-Kinases; Endothelial Cells; Imidazoles; Mice; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Vascular Malformations	2022

Article

Year

The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib.

EMBO molecular medicine, 2022, 07-07, Volume: 14, Issue:7

Topics: Aminopyridines; Animals; Class I Phosphatidylinositol 3-Kinases; Endothelial Cells; Imidazoles; Mice; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Vascular Malformations

2022